A process for producing cellulolytic and/or hemicellulolytic enzymes with a strain of microorganism belonging to the family of filamentous fungi. The process includes growing the fungi in an aqueous culture medium, in the presence of at least one carbon-based growth substrate, in a stirred and aerated bioreactor. It also includes the production of enzymes, starting with the aqueous culture medium in the presence of at least one inductive carbon-based substrate and also inducing the production of hydrophobins. Further, at least a portion of the hydrophobins produced in step (b) are reintroduced into the growth step (a).

A process for producing cellulolytic and/or hemicellulolytic enzymes with a strain of microorganism belonging to the family of filamentous fungi. The process includes growing the fungi in an aqueous culture medium, in the presence of at least one carbon-based growth substrate, in a stirred and aerated bioreactor. It also includes the production of enzymes, starting with the aqueous culture medium in the presence of at least one inductive carbon-based substrate and also inducing the production of hydrophobins. Further, at least a portion of the hydrophobins produced in step (b) are reintroduced into the growth step (a).

Royal jelly honey produced by nurse bees, honey and milk has great values in human health and/or beauty. This invention aims to produce royal jelly honey substitute, honey substitute, animal free milk without the need for bees or cows or goats. First, recombinant major royal jelly proteins (MRJPs), defensin-1, and milk proteins are produced by microbes (such as bacteria, yeasts, or fungi) using precision fermentation. The MRJPs, defensin-1 or milk proteins are then formulated with vitamins, water, minerals, fats, salt and/or amino acids to produce a bee-free royal jelly honey substitute, bee-free honey substitute or animal free milk. MRJPs can also be formulated with vitamins, water, minerals, fats, salt, amino acids and recombinant milk proteins to produce animal-free milk or milk substitutes with supplemental MRJPs. Plant-based milks can also be supplemented with MRJPs and recombinant milk proteins.

Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.

The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.

The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.

A method of modifying a glycosylation pattern of a polypeptide-of-interest in a plant or plant cell is provided. The method comprising expressing in a plant or plant cell transformed to express at least one glycosidase in a subcellular compartment, a nucleic acid sequence encoding the polypeptide-of-interest, such that the at least one glycosidase and the polypeptide-of-interest are co-localized to the subcellular compartment of the plant or plant cell, thereby modifying the glycosylation pattern of the polypeptide-of-interest in the plant or plant cell.

In order to develop tools and methods useful in a variety of applications, including the research and development of medical treatments which involve the modification of collagen protein and use of the same, the present invention provides a modified collagen protein expressed in a transformed cell and capable of forming collagen fibers outside of the cell, wherein the transformation is performed by introducing, into the cell, polynucleotides coding the modified collagen protein.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

Described herein are engineered organelles comprising multi-component proteins from different species incorporated into a membrane structure with interior and exterior aspects. In one embodiment the artificial organelle incorporates one or more protein complexes that absorb optical energy and catalyze electron transfer in biochemical reactions that can be used to reduce NAD.sup.+ to NADH or analogues thereof.